Coulter Partners Recruits Chief Medical Officer for Neumirna Therapeutics
June 19, 2026 – Life sciences recruiting specialist Coulter Partners has placed Ferenc Tracik as chief medical officer of Neumirna Therapeutics. “Neumirna has reached an inflection point: the question is no longer whether the science works, but how quickly we can translate it into an option for patients with urgent unmet need. Ferenc has the experience to get us there,” said Ellen Donnelly, CEO of Neumirna Therapeutics. “Alongside his leadership in CNS development and global regulatory strategy, he has played a key role in bringing an ASO therapy for a neurological disease to patients.
“We truly valued the partnership and strategic insight provided by Coulter Partners throughout this search,” Ms. Donnelly said. “Their deep understanding of the ASO and RNA landscape allowed them to move with precision, identifying a CMO who possesses both the technical depth and the commercial launch experience necessary for our next phase of growth.”
“It was a great pleasure to support Neumirna during this critical phase of their transition toward the clinic,” said Nanna Soni, client partner at Coulter Partners. “The technology represents the next frontier in treating drug-resistant epilepsy and other complex neuro-disorders, and identifying a physician-leader like Ferenc was critical. He is uniquely qualified to help bridge the gap between Neumirna’s pioneering research and transformative patient care. Our collaboration with CEO Ellen Donnelly and her deeply committed board resulted in a seamless and highly productive search process for this pivotal role.”
Dr. Tracik is a physician-leader with more than two decades of expertise in neurological and rare disease drug development. At Neumirna, he will oversee medical and clinical strategy, focusing on patient safety, regulatory interactions, and external medical affairs. Dr. Tracik will partner with Neumirna’s CDO to guide lead program NMT.001 into the clinic in early 2027 and lend his clinical perspective to Neumirna’s preclinical program in Parkinson’s disease.
Most recently, Dr. Tracik served as CMO at NeuroSense Therapeutics, he led global Phase 2 programs in ALS and Alzheimer’s disease, including a successful IND submission to the FDA. Previously, he served as vice president, Europe, Canada, and partner markets at Biogen, where he led the European medical launch of an antisense oligonucleotide (ASO) for Spinal Muscular Atrophy (SMA). During his tenure at Biogen, Dr. Tracik established a highly recognized multinational SMA registry in collaboration with leading experts and contributed to one of the largest global Expanded Access Programs in SMA. His career also includes significant leadership roles at Novartis and Teva.
Related: Coulter Partners Recruits CEO for Babraham Research Campus
Neumirna Therapeutics is a biotechnology company developing miRNA-targeted therapies for neurological disorders dedicated to transforming patients’ lives. Founded in 2020 in Copenhagen, Denmark by Dr. Henrik Klitgaard and Sakari Kauppinen, the company is advancing therapies for neurological diseases through the modulation of microRNAs. The company completed its Series A financing in January 2025 and is supported by Invivo Partners, Angelini Ventures and Innovestor, with the founders remaining actively involved.
Serving the Life Sciences Sector
Coulter Partners is a board- and senior-level global executive search specialist focused exclusively on life sciences. The firm works closely with those at the cutting edge of innovation in the industry to understand their challenges. With an extensive global network and expertise gained over 25 years in the sector, Coulter Partners is a trusted leadership adviser in the pharmaceuticals, biotechnology, medical technology, diagnostics, health-tech, CRO, and services sectors.
The Select Guide to America’s Top 250 Executive Search Firms
Hunt Scanlon Media proudly presents the Select Guide to America’s Top 250 Executive Search Firms.
This comprehensive online directory is your definitive resource for finding the best executive search firms to serve your talent needs.
Our guide is meticulously curated to connect you with leading firms that specialize in various industries and functions, ensuring you find the perfect match for your executive recruitment needs.
Coulter Partners also works closely with the global investor community, hiring for their own teams as well as building the boards and executive leadership teams of their portfolio companies. Coulter Partners’ team of 95 completes over 260 assignments a year working from 14 offices across the U.K., EMEA, the U.S., and APAC.
Bianca Coulter founded Coulter Partners in 2003 and has 25 years’ experience of board and C-level global search, building the leadership teams of early-stage, mid-cap, and global multinationals in over 20 countries. Through appointing leadership, Ms. Coulter channels her judgment and expertise to impact patient benefit and assist those at the cutting edge of life science to achieve their goals.
Related: Coulter Partners Recruits Chief Scientific Officer for Laigo Bio
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
